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Background: TNF-a and IL-6 have been shown to be associated with insulin resistance in T2 DM subjects.
However, their causal role in the development of diabetes is still unsettled.
Subjects and methods: In the present study 106 prediabetic subjects (17 IFG, 60 IGT, 29 IFG-IGT) were
studied along with age- and BMI-matched 56 healthy controls. Insulin was measured by ELISA; TNF-a
and IL-6 were measured by chemiluminescence-based EIA.
Results: Fasting serum TNF-a and fasting serum IL-6 levels were not signiﬁcantly different among the
groups. However, a signiﬁcant association of TNF-a (p < 0.013) with prediabetic (IGR) state on binary
logistic regression analysis was shown when the effects of sex, BMI, WHR, HOMA B and HOMA S were
adjusted. On multinomial logistic regression analysis a signiﬁcant positive association of TNF-a was
observed with IGT and IFG-IGT subjects (p = 0.008, p = 0.008) when the effects of sex, BMI, WHR, HOMA
B and HOMA S were adjusted. On multiple linear regression analysis TNF-a showed a signiﬁcant positive
association with insulin secretory capacity when adjusting the effects of the confounding factors.
Conclusions: TNF-a is positively associated with IGT and IFG-IGT state and may have a causal relation
with insulin secretory defect in IGR or prediabetic subjects.
 2010 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.1. Introduction
Inﬂammatory mechanisms play a key role in the pathogenesis
of diabetes mellitus. Individuals who progress to type 2 diabetes
display features of low-grade inﬂammation before the onset of
diabetes. This low-grade inﬂammation has been suggested as
being involved in the pathogenetic processes that cause type 2
diabetes [1]. Several humoral markers of inﬂammation are ele-
vated in humans with type 2 diabetes [2]. Epidemiological evi-
dence suggests that inﬂammatory markers predict the
development of diabetes and glucose disorders [3]. Tumor necro-
sis factor-a (TNF-a) and Interleukin-6 (IL-6) are two major proin-
ﬂammatory markers or cytokines, acting primarily as autocrine
and/or paracrine factors. TNF-a is secreted by several types of
cells such as macrophages, monocytes, neutrophils and T-cells. In-
creased TNF-a expression has been observed in adipose tissue de-
rived from obese rodents or human subjects and has beenellitus. Published by Elsevier Ltd.
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Oimplicated as an important factor in obesity-associated insulin
resistance and pathogenesis of type 2 diabetes [4]. Multiple
mechanisms have been suggested to account for the metabolic ef-
fects of TNF-a. These include the downregulation of genes re-
quired for normal insulin action, the negative regulation of
PPARc an important insulin-sensitizing nuclear receptor, the di-
rect effects on insulin signaling and the induction of elevated free
fatty acids via the stimulation of lipolysis [5]. On the other hand,
interleukin-6 (IL-6) is an immune protein of the hematopoietins
family. It is a monomer of 184 amino acids produced by T-cells,
macrophages and endothelial cells found on a single gene located
at 7p21. It is secreted from adipose tissue during resting condi-
tions and from muscle during strenuous exercise [6]. The role of
IL-6 in insulin resistance is controversial [7].
TNF-a and IL-6 are increased in subjects with IGT (female Turk-
ish subject and Italian Caucasians) [8,9] but another study contra-
dicts this result [10]. Although TNF-a and IL-6 are claimed to be
associated with insulin resistance in type 2 diabetes [11,12], very
few studies exist where all the three IGR (Impaired Glucose Regu-
lation) (IFG, IGT, IFG-IGT) groups were studied regarding TNF-a
and IL-6, which are important to know whether these adipocytoki-
ne hormones are the causal factors in the development of type 2
diabetes. Hence, the present study aims to ﬁnd out the relationpen access under CC BY-NC-ND license.
Table 1
Clinical and biochemical characteristics of the study subjects (IFG, IGT and IFG-IGT).
Parameters Controls (n = 56) Prediabetic subjects (n = 106)
IFG (n = 17) IGT (n = 60) IFG-IGT (n = 29)
Age (years) 38 ± 6 43 ± 6 41 ± 7 43 ± 8
Body mass index (kg/m2) 25.4 ± 3.9 26.6 ± 4.6 26.5 ± 3.5 26.1 ± 4.2
Waist-to-hip ratio 0.90 ± 0.05 0.92 ± 0.04 0.91 ± 0.05 0.93 ± 0.05*
Neck circumference (cm) 35.4 ± 3.0 36.1 ± 2.8 35.3 ± 3.6 37.0 ± 3.7
MUAC (mm) 296 ± 28 302 ± 33 306 ± 24 300 ± 32
Triceps (mm) 14.4 ± 5.2 15.5 ± 7.1 15.4 ± 4.9 15.5 ± 5.7
Body fat mass (%) 29.2 ± 6.2 29.3 ± 7.3 29.7 ± 6.0 29.2 ± 0.5
Systolic blood pressure (mm Hg) 114 ± 8 120 ± 21 121 ± 16 124 ± 19*
Diastolic blood Pressure (mm Hg) 76 ± 8 82 ± 9 82 ± 9* 81 ± 9*
Fasting glucose (mmol/l) 5.1 ± 0.4 6.2 ± 0.3* 5.4 ± 0.2* 6.4 ± 0.3*
2 h Glucose (mmol/l) 5.8 ± 1.1 6.7 ± 0.9* 9.6 ± 0.8* 8.9 ± 1.0*
Triglyceride (mg/dl) 149 (52–376) 184 (61–415) 165 (50–491) 191 (50–401)
Cholesterol (mg/dl) 188 (90–261) 194 (150–259) 196(105–298) 200 (124–261)
HDL cholesterol (mg/dl) 31 (18–59) 28 (15–40) 30 (18–54) 29 (21–43)
LDL cholesterol (mg/dl) 127 (45–194) 124 (74–153) 132 (62–239) 132 (77–192)
Serum GPT (U/L) 27 (12–122) 16 (10–74) 23 (10–162) 32 (16–92)
Serum creatinine (mg/dl) 1.1 (0.8–1.6) 1.1(0.9–1.3) 1.1 (0.8–1.4) 1.1 (0.8–1.6)
Fasting insulin (pmol/l) 50 (7–155) 64 (23–121) 66 (6–237) 77 (22–181)*
HOMA B 99 (21–187) 76 (39–113)* 99 (26–278) 79 (37–157)*
HOMA S 88 (29–554) 68 (36–180) 66 (19–660) 55 (24–193)*
TNF-a (pg/ml) 9.9 (4.8–28.9) 11.1 (5.5–24.3) 14.6 (4.2–47.5) 10.3 (5.1–36.7)
IL-6 (pg/ml) 2.8 (1.1–10.6) 3.2 (1.3–10.5) 3.1 (1.0–17.8) 3.3 (1.3–10)
HOMA %B = B cell function and HOMA %S = insulin sensitivity, assessed by homeostasis model assessment; TNF-a = tumor necrosis factor-alpha; IL-6 = interleukin-6.
* p < 0.05, signiﬁcantly different compared to controls when using Student’s ‘t’ test.
166 M. Hossain et al. / International Journal of Diabetes Mellitus 2 (2010) 165–168of TNF-a and IL-6 with insulin secretory capacity or insulin sensi-
tivity in prediabetic subjects (IFG, IGT and combined IFG-IGT).2. Materials and methods
This cross-sectional observational study was conducted in the
Research Division, Bangladesh Institute of Research and Rehabilita-
tion in Diabetes, Endocrine and Metabolic Disorders (BIRDEM),
Dhaka. A group of 17 impaired fasting glucose (IFG), 60 impaired
glucose tolerance (IGT) and 29 combined IFG-IGT subjects were re-
cruited purposively from the Out-Patient Department (OPD) of
BIRDEM, along with a group of 56 age-, sex- and BMI-matched
healthy subjects without a family history of diabetes, as controls
from the friend circle of the Impaired Glucose Regulation (IGR)
subjects considering the same socio-economic status. Subjects
were considered as IFG, IGT and IFG-IGT using the WHO guidelines,
1999 [13]. Written consent was taken from all the volunteers; clin-
ical examination was done by a registered physician using a prede-
signed questionnaire. Anthropometric measurements were taken
using standard methods. Subjects were requested to come on a
prescheduled morning after overnight fasting for the fasting blood
sample; subjects were then given 75 gm of anhydrous glucose, dis-
solved in 250 ml water. Blood was taken by venepuncture at fast-
ing condition, and 2 h after glucose loading. Fasting and
postprandial serum glucose was measured using the glucose–oxi-
dase method, and the fasting serum lipid proﬁle (cholesterol, tri-
glyceride and HDL) was determined by enzymatic colorimetric
method, fasting serum creatinine by alkaline picrate method, and
serum SGPT by UV-spectrophotometric method using commercial
kits (Randox Laboratories Ltd., UK). Serum LDL was calculated
using the formula of Friedewald [14]. Fasting serum insulin levels
were determined through the enzyme-linked immunosorbent as-
say (ELISA) method (Linco Research Inc., USA). Fasting serum
TNF-a and IL-6 concentrations were measured by solid-phase, en-
zyme-labeled, chemiluminescent immunometric assay (IMMU-
LITE, DPC, USA). Insulin secretory capacity (HOMA B%) and
insulin sensitivity (HOMA S%) were calculated from fasting glucose
and fasting insulin using HOMA-CIGMA software [15].3. Statistical analysis
Statistical analysis was performed using SPSS (Statistical Pack-
age for Social Science) software for Windows version 10 (SPSS
Inc., Chicago, Illinois, USA). Fasting levels of biomarkers (for glu-
cose both fasting & postprandial) were used for statistical analysis.
All the data were expressed as mean ± SD (standard deviation),
median (range) and/or percentage (%) as appropriate. The statisti-
cal signiﬁcance of differences between the values was assessed
by ANOVA or Mann–Whitney U test (as appropriate). Logistic and
Multiple regressions were performed among on the parameters.
A two-tailed p value of <0.05 was considered as statistically
signiﬁcant.4. Results
Subjects with IFG-IGT had signiﬁcantly higher waist–hip ratio
(WHR) (p = 0.04), systolic blood pressure (p = 0.03), and diastolic
blood pressure (p = 0.04) compared to controls. Diastolic blood
pressure was also signiﬁcantly higher in IGT subjects (p = 0.02)
compared to controls. Fasting serum insulin was signiﬁcantly high-
er in IFG-IGT (p = 0.004) group compared to controls. Insulin secre-
tory capacity (HOMA B) was signiﬁcantly lower in IFG (p = 0.004)
and IFG-IGT (p = 0.008) subjects compared to controls. Insulin sen-
sitivity (HOMA S) was signiﬁcantly lower in IFG-IGT (p = 0.004)
compared to controls. Fasting serum TNF-a and IL-6 levels were
not signiﬁcantly different in any of the prediabetic group compared
to controls (Table 1).4.1. Logistic regression analysis
In binary logistic regression analysis, IFG, IGT and IFG-IGT sub-
jects were considered together as a single IGR group (Table 2) and
it was found that TNF-a was positively associated (p = 0.013) with
IGR subjects adjusted by age, sex, BMI, HOMA B and HOMAS. In the
same analysis HOMA B and HOMA S were negatively associated
(p = 0.003 and p = 0.001 respectively) with IGR subjects (Table 2).
Considering IFG, IGT and IFG-IGT as single groups, we performed
Table 2
Logistic regression analysis of TNF-a and IL-6 adjusted with confounding factors
(Taking control as reference).
Group Variables Beta S.E. p value Exp(B)
Binary logistic regression
IGR TNF-a 0.111 0.045 0.013 1.118
IL-6 0.033 0.113 0.771 0.968
HOMA B 0.025 0.008 0.003 0.975
HOMA S 0.035 0.011 0.001 0.966
BMI 0.015 0.067 0.825 0.985
Age 0.177 0.046 0.000 1.194
Sex 0.462 0.534 0.387 1.587
Constant 1.992 2.896 0.491 0.136
Multinomial logistic regression
IFG Intercept 7.575 5.291 0.152
TNF-a 0.079 0.067 0.235 1.082
IL-6 0.095 0.171 0.581 1.099
HOMA B 0.118 0.030 0.001 0.888
HOMA S 0.066 0.020 0.001 0.936
BMI 0.064 0.106 0.543 1.066
Age 0.130 0.059 0.028 1.139
Sex 0.380 0.852 0.656 0.684
IGT Intercept 5.613 3.311 0.090
TNF-a 0.125 0.047 0.008 1.133
IL-6 0.022 0.123 0.861 0.979
HOMA B 0.009 0.009 0.342 0.991
HOMA S 0.023 0.012 0.050 0.978
BMI 0.043 0.072 0.548 0.958
Age 0.181 0.047 0.000 1.198
Sex 0.987 0.587 0.092 2.684
IFG + IGT Intercept 13.390 5.247 0.011
TNF-a 0.141 0.053 0.008 1.151
IL-6 0.100 0.183 0.585 0.905
HOMA B 0.130 0.028 0.001 0.878
HOMA S 0.094 0.021 0.001 0.911
BMI 0.052 0.108 0.628 0.949
Age 0.127 0.059 0.030 1.136
Sex 0.010 0.817 0.990 1.010
Table 3
Multiple linear regression analysis of different factors affecting HOMA B in IGR
subjects.
HOMA B vs Controls IGR
Beta p value Beta p value
TNF-a 1.395 0.174 0.238 0.023
IL-6 0.002 0.992 0.044 0.668
BMI 0.427 0.026 0.244 0.020
Age 0.028 0.880 0.084 0.407
Sex 0.052 0.804 0.005 0.961
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niﬁcant association (p = 0.008) with IGT and IFG-IGT subjects when
age, sex, BMI, HOMA B, HOMA S and IL-6 were adjusted. In the
same analysis, it was shown that HOMA B had negative association
(p = 0.001) with IFG and IFG-IGT subjects, and HOMA S also had
negative association with IFG (p = 0.001), IGT (p = 0.05) and IFG-
IGT (p = 0.001) subjects (Table 2).4.2. Multiple linear regression analysis
In multiple linear regression analysis, TNF-a has shown a signif-
icant positive association with insulin secretory capacity (HOMA B)
when adjusting the effects of the confounding factors - age, sex and
BMI in IGR subjects (Table 3). Such an association of IL-6 with pre-
diabetic state and its underlying defects was not evident. Neither
TNF-a nor IL-6 in IGR subjects has found any association with insu-
lin resistance according to the data.5. Discussion
It has been suggested that type 2 diabetes mellitus is a disease
of the innate immune system responsible for an ongoing cytokine-
mediated acute phase response and low-grade chronic inﬂamma-
tion, which may be involved in the atherosclerosis of diabetes mel-
litus [16]. Therefore it seems important to determine whether
signs of an activated innate immune system are present before
the onset of type 2 diabetes mellitus. Epidemiological evidence
suggests that inﬂammatory markers such as TNF-a and IL-6 predict
the development of diabetes and glucose disorders [3]. TNF-a con-
tributes to the pathogenesis of insulin resistance, type 2 diabetes,
and abnormal adiposity or lipid disorders [17]. Some authors have
found increased serum TNF-a and IL-6 concentrations in type 2 DM
and IGT subjects [9,18] but Choi et al. (2004) [10] have not found
any association of TNF-a and IL-6 with IGT. However, TNF-a and
IL-6 have not been extensively studied in all the three groups of
IGR (IFG, IGT and IFG-IGT) subjects. It is important to know
whether it has any relation with insulin resistance and insulin
secretory defects which appear at the prediabetic stage.
In this study, we have not found any increment of serum TNF-a
in IGR subjects as compared to controls. TNF-a has been shown to
be secreted in the adipocytes of both mice and human [19]. In the
adipose tissue of rodents with genetic obesity and insulin resis-
tance, increased levels of both RNA and protein of TNF-a were de-
scribed, supporting a link between obesity, diabetes and TNF-a.
Body Mass Index (BMI) of the subjects in the present study was
of normal range, and there was no signiﬁcant difference between
the control subjects and the IGR groups (IFG, IGT and IFG-IGT),
which may be the reason for the similar serum TNF-a concentra-
tions among the groups in the studied subjects. A study on Korean
subjects showed that serum TNF-a concentration was not elevated
in prediabetic patients, as compared to controls [10], which sup-
ports the present study and gives a similar reason for the subjects
not being obese. However, when the effects of HOMA B, HOMA S,
age, sex and BMI were excluded using binary logistic regression,
serum TNF-a levels in the present study showed a signiﬁcant asso-
ciation with IGR. With regards to multinomial regression analysis,
to observe the association in individual groups of IGR, TNF-a
showed a positive signiﬁcant association (p = 0.008) with IGT and
IFG-IGT subjects when age, sex, BMI, HOMA B, HOMA S and IL-6
were adjusted for.
After this, we considered whether TNF-a is associated with the
principal features of type 2 diabetes, i.e., insulin resistance or insu-
lin secretory defect. On multiple linear regression analysis with
HOMA B and HOMA S as dependent variables, TNF-a showed a sig-
niﬁcant positive association with insulin secretory capacity when
adjusting the effects of the confounding factors - age, sex and
BMI in IGR subjects. Thus, there may be a causal relationship be-
tween TNF-a with insulin secretory defect in prediabetic and IGR
subjects.
Circulating IL-6 levels have been reported to be elevated in sub-
jects with type 2 diabetes [24]. Moreover, IL-6 independently pre-
dicts the risk of type 2 diabetes [25]. We have not found any
association of serum IL-6 level with IGR, or with any of the two
principal features of diabetes. Serum IL-6 levels in IFG, IGT, IFG-
IGT and even in control subjects are controversial [8]. Earlier stud-
ies have documented that serum IL-6 concentrations are higher in
IGT than in NGT (Normal Glucose Tolerance) [11,20,21], while
other studies have found no elevation in serum IL-6 concentrations
in prediabetic patients, as compared to controls [10]. A study
undertaken with Italian Caucasians has shown that IGT and type
2 DM, but not IFG, are associated with elevated IL-6 levels [9]. This
may happen due to variations in racial, environmental or geo-
graphical conditions or nutritional status.
168 M. Hossain et al. / International Journal of Diabetes Mellitus 2 (2010) 165–168Although binary and multinomial regression analyses have
shown signiﬁcant association of TNF-a with IGR, no difference of
circulating concentrations of TNF-a and IL-6 was found between
controls and IGR subjects. Studies suggest that in type 2 diabetes
mellitus, both TNF-a and IL-6 are increased [9,22,23]. Therefore
the present study suggests that insulin resistance in type 2 diabe-
tes mellitus may lead to, rather than be the consequence of, raised
concentrations of inﬂammatory mediators.
In conclusion, it may be stated that TNF-a is positively associ-
ated with IGT and IFG-IGT and may have a causal relation with
an insulin secretory defect in IGR or prediabetic subjects.
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